/ /

  • linkedin
  • Increase Font
  • Sharebar

    Ranibizumab provides solid safety, efficacy in real-world population

    Data at 1 and 2 years follow-up indicated expected relative preservation of visual acuity

     

    Take-home message: Treatment with ranibizumab is safe and efficacious for currently licensed indications, according to an interim analysis of data from the LUMINOUS Study.

     

    Sydney, Australia—An interim analysis of data from the LUMINOUS Study reconfirmed that treatment with ranibizumab (Lucentis, Novartis) is safe and efficacious for all the current licensed indications.

    The LUMINOUS Study is a 5-year, observational, non-interventional, multicenter, international study designed to provide real-world analysis of the data obtained from patients undergoing treatment for neovascular age-related macular degeneration (AMD), visual impairment from diabetic macular edema (DME) and macular edema secondary to retinal vein occlusion, and choroidal neovascularization secondary to pathologic myopia.

    Paul Mitchell, MD, PhD, reviewed the data on behalf of the LUMINOUS Study group from the fourth year of the study, i.e., the second interim analysis, that included 20,000 patients evaluated at baseline—10,000 of whom were followed for 1 year after treatment, and 2,000 were followed for 2 years.

    The final data analysis in March 2016 included 30,000 patients who have been followed for from 1 to 4 to 5 years at 600 sites with more than 40 countries represented.

    Study strengths

    The strength of the study is the wide geographic diversity, according to Dr. Mitchell, professor of ophthalmology, Centre for Vision Research, Department of Ophthalmology, and Westmead Millennium Institute, University of Sydney, Australia. He explained that the Despite the study having begun in Canada, the United Kingdom, and Australia—from which most of the patients hailed—substantial percentages of patients are from Asia and Eastern and Western Europe.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results